drugset / Trial / NCT03823703
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)
RandomizedParallel-groupTriple-blindTreatment
Summary
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis (NASH).
Timeline
- Start
- 2020-11-04
- Primary completion
- 2021-04-05
- Completion
- 2021-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Miricorilant | Small molecule | 600 mg | Oral |
| Subject | Miricorilant | Small molecule | 900 mg | Oral |